“Toxicology studies were conducted solely using cynomolgus monkeys because other species available for toxicity testing are not pharmacologically responsive to obinutuzumab.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Why that species
Binds cynomolgus (not rodent) CD20 with affinity and ADCC potency similar to human CD20
“Obinutuzumab binds to Cynomolgus monkey (but not rodent) CD20 with an affinity and ADCC potency similar to that of human CD20; consequently, the Cynomolgus monkey was considered the only appropriate species in which to assess the safety of obinutuzumab.”
No surrogate; the clinical antibody was tested in cynomolgus monkeys
“Toxicology studies were conducted solely using cynomolgus monkeys because other species available for toxicity testing are not pharmacologically responsive to obinutuzumab.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗